scholarly journals Profil Paparan Asap Rokok Lingkungan pada Pasien Kanker Payudara di Sumatera Barat Tahun 2020

2020 ◽  
Vol 1 (2) ◽  
Author(s):  
Fathma Mardhotilla
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cigarette Smoke ◽  
Descriptive Study ◽  
University Hospital ◽  
Cigarette Smoke Exposure ◽  
Modifiable Risk Factors ◽  
Breast Cancer Patients ◽  
West Sumatra ◽  
Common Malignancy

Latar Belakang. Kanker payudara merupakan keganasan pada perempuan terbanyak ke-dua di dunia dan merupakan keganasan dengan tingkat kejadian tertinggi ke-dua di Indonesia. Kanker payudara disebabkan oleh faktor risiko yang dapat dimodifikasi dan tidak dapat dimodifikasi. Salah satu faktor risiko yang dapat dimodifikasi yang dicurigai menyebabkan kanker payudara adalah paparan asap rokok lingkungan, baik paparan asap rokok dari suami, rekan kerja, dan orang tua saat kecil. Objektif. Mengetahui profil paparan asap rokok lingkungan pada pasien kanker payudara di Sumatera Barat tahun 2020 Metode. Penelitian ini merupakan penelitian deskriptif dengan jumlah sampel sebanyak 107 orang pasien yang sedang rawat jalan atau rawat inap di di Bagian Bedah RSUP Dr. M. Djamil, RS Pendidikan Universitas Andalas, dan RSI Ibnu Sina Padang dari Januari 2020 – Maret 2020. Hasil. Sebanyak 90 (84,1%) pasien terpapar asap rokok lingkungan. Simpulan. Pasien yang terpapar asap rokok lingkungan lebih banyak lima kali lipat daripada yang tidak terpapar asap rokok lingkungan. Kata kunci:  kanker payudara, faktor risiko yang dapat dimodifikasi, paparan asap rokok lingkungan, sumatera barat   Background. Breast cancer is the second most common malignancy in women in the world and the second highest malignancy incidence rate in Indonesia. Breast cancer is caused by modifiable and non-modifiable risk factors One of the modifiable risk factors factor suspected of causing breast cancer is exposure to environmental cigarette smoke, such as exposure to cigarette smoke from  husband, coworkers, and parents as a child. Objective. To determine the he profile of environmental cigarette smoke exposure in breast cancer patients in West Sumatra in 2020. Methods. This research is a descriptive study with a sample of 107 patients who are being treated as outpatients or inpatients in the Department of Surgery Dr. M. Djamil, Andalas University Hospital, and Ibnu Sina Padang Hospital from January 2020 - March 2020  Results. 90 (84.1%) patients were exposed to environmental cigarette smoke  Conclusion. Patients who are exposed to environmental cigarette smoke are lima times more likely than those who are not exposed Keyword: breast cancer, modifiable risk factor, environmental cigarette smoke, West Sumatra

Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients

2014 ◽  
Vol 95 (1) ◽  
pp. 98-103 ◽  
Author(s):  
Kimberly R. Jacob Arriola ◽  
Tamara A. Mason ◽  
Kari Ann Bannon ◽  
Carol Holmes ◽  
Cecil Lamonte Powell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Adjuvant Endocrine Therapy ◽  
Modifiable Risk Factors ◽  
Breast Cancer Patients

scholarly journals Distinct employment interference profiles in patients with breast cancer prior to and for 12 months following surgery

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Raymond Javan Chan ◽  
Bruce Cooper ◽  
Louisa Gordon ◽  
Nicolas Hart ◽  
Chia Jie Tan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Risk Factors ◽  
Breast Cancer Surgery ◽  
Modifiable Risk Factors ◽  
Advanced Stage ◽  
Breast Cancer Patients ◽  
High Group ◽  
Stage Disease

Abstract Purpose To identify subgroups of female breast cancer patients with distinct self-reported employment interference (EI) profiles and determine which demographic, clinical, and symptom characteristics, and quality of life outcomes were associated with subgroup membership. Methods Women with breast cancer (n = 385) were assessed for changes in EI over ten times, from prior to, through 12 months after breast cancer surgery. Latent profile analysis (LPA) was used to identify subgroups of patients with distinct EI profiles. Results Three distinct EI profiles (i.e., None – 26.2% (n = 101), Low – 42.6% (n = 164), High – 31.2% (n = 120)) were identified. Compared to the None and Low groups, patients in the High group were more likely to be younger. Higher proportions in the High group were non-White, pre-menopausal prior to surgery, had more advanced stage disease, had received an axillary lymph node dissection, had received neoadjuvant chemotherapy, had received adjuvant chemotherapy, and had a re-excision or mastectomy on the affected breast within 6 months after surgery. In addition, these patients had lower quality of life scores. Compared to the None group, the High group had higher levels of trait and state anxiety, depressive symptoms, fatigue and sleep disturbance and lower levels of cognitive function. Conclusions This study provides new knowledge regarding EI profiles among women in the year following breast cancer surgery. The non-modifiable risk factors (e.g., younger age, being non-White, having more advanced stage disease) can inform current screening procedures. The potentially modifiable risk factors can be used to develop interventions to improve employment outcomes of breast cancer patients.

Incidence and Risk Factors of the Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab

2018 ◽  
Vol 35 (2) ◽  
pp. 177-183
Author(s):  
정지혜 ◽  
여미진 ◽  
박애령 ◽  
황보신이 ◽  
나현오 ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Breast Cancer Patients

scholarly journals An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study

2021 ◽  
Vol 11 (3) ◽  
pp. 484-493
Author(s):  
Jukapun Yoodee ◽  
Aumkhae Sookprasert ◽  
Phitjira Sanguanboonyaphong ◽  
Suthan Chanthawong ◽  
Manit Seateaw ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Breast Cancer Patients ◽  
Ventricular Ejection Fraction ◽  
Factors Associated ◽  
Palliative Intent ◽  
Increased Risk

Anthracycline-based regimens with or without anti-human epidermal growth factor receptor (HER) 2 agents such as trastuzumab are effective in breast cancer treatment. Nevertheless, heart failure (HF) has become a significant side effect of these regimens. This study aimed to investigate the incidence and factors associated with HF in breast cancer patients treated with anthracyclines with or without trastuzumab. A retrospective cohort study was performed in patients with breast cancer who were treated with anthracyclines with or without trastuzumab between 1 January 2014 and 31 December 2018. The primary outcome was the incidence of HF. The secondary outcome was the risk factors associated with HF by using the univariable and multivariable cox-proportional hazard model. A total of 475 breast cancer patients were enrolled with a median follow-up time of 2.88 years (interquartile range (IQR), 1.59–3.93). The incidence of HF was 3.2%, corresponding to an incidence rate of 11.1 per 1000 person-years. The increased risk of HF was seen in patients receiving a combination of anthracycline and trastuzumab therapy, patients treated with radiotherapy or palliative-intent chemotherapy, and baseline left ventricular ejection fraction <65%, respectively. There were no statistically significant differences in other risk factors for HF, such as age, cardiovascular comorbidities, and cumulative doxorubicin dose. In conclusion, the incidence of HF was consistently high in patients receiving combination anthracyclines trastuzumab regimens. A reduced baseline left ventricular ejection fraction, radiotherapy, and palliative-intent chemotherapy were associated with an increased risk of HF. Intensive cardiac monitoring in breast cancer patients with an increased risk of HF should be advised to prevent undesired cardiac outcomes.

scholarly journals Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Guohua Liang ◽  
Wenjie Ma ◽  
Yanfang Zhao ◽  
Eryu Liu ◽  
Xiaoyu Shan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Prediction Model ◽  
Cancer Patients ◽  
Blood Circulation ◽  
Pegylated Liposomal Doxorubicin ◽  
Dose Intensity ◽  
Breast Cancer Patients ◽  
Hand Foot Syndrome ◽  
Peripheral Blood Circulation

Abstract Background Hand-foot syndrome (HFS) is a side effect of skin related to pegylated liposomal doxorubicin (PLD) application. Moderate to severe hand-foot syndrome (MSHFS) might have a serious impact on patients’ quality of life and treatment. However, information on risk factors for the development of MSHFS is still limited. To analyze the risk factors for PLD-induced MSHFS in breast cancer patients and constructed a logistic regression prediction model. Methods We conducted a retrospective analysis of breast cancer patients who were treated with a PLD regimen in the Tumor Hospital of Harbin Medical University from January 2017 to August 2019. A total of 26 factors were collected from electronic medical records. Patients were divided into MSHFS (HFS > grade 1) and NMHFS (HFS ≤ grade 1) groups according to the NCI classification. Statistical analysis of these factors and the construction of a logistic regression prediction model based on risk factors. Results A total of 44.7% (206/461) of patients developed MSHFS. The BMI, dose intensity, and baseline Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) levels in the MSHFS group, as well as good peripheral blood circulation, excessive sweat excretion, history of gallstones, and tumour- and HER2-positive percentages, were all higher than those in the NMHFS group (P < 0.05). The model for predicting the occurrence of MSHFS was P = 1/1 + exp. (11.138–0.110*BMI-0.234*dose intensity-0.018*baseline ALT+ 0.025*baseline AST-1.225*gallstone history-0.681* peripheral blood circulation-1.073*sweat excretion-0.364*with or without tumor-0.680*HER-2). The accuracy of the model was 72.5%, AUC = 0.791, and Hosmer-Lemeshow fit test P = 0.114 > 0.05. Conclusions Nearly half of the patients developed MSHFS. The constructed prediction model may be valuable for predicting the occurrence of MSHFS in patients.

Sign in / Sign up

Export Citation Format

Share Document